What is the reason that you haven't read anything (up-to-date) about this here yet? $CVAC (-0,22%)
$BNTX (+0,44%)

https://www.handelsblatt.com/unternehmen/industrie/pharmabranche-biontech-startet-uebernahme-von-curevac/100166847.html

As every Sunday, the most important news from the past week, as well as the most important dates for the coming week.

Also as a video:

https://youtube.com/shorts/Qnq0Hgw02ok?si=c1DdZaCBPcjb9KK5

Monday:

The Japanese economy contracted slightly less than feared in the first quarter. However, there is still a risk of recession. The annualized figure was only 0.2 % instead of 0.7 %.

https://www.wsj.com/economy/japans-economy-at-risk-of-technical-recession-revised-data-shows-dde9dd61

Wednesday:

The tariffs have hardly had any impact on US inflation so far, but the inflation rate has nevertheless risen to 2.4%. Both core inflation and actual inflation were 10 basis points below expectations, with housing costs being the strongest driver of inflation.

https://www.handelsblatt.com/finanzen/geldpolitik/inflation-us-teuerung-zieht-im-mai-leicht-an/100134062.html

Thursday:

Tragic accident in India with a $BA (+1,5%) Boeing aircraft. Unfortunately, accidents involving Boeing aircraft occur at regular intervals. The cause of the crash remains unclear for the time being.

https://www.spiegel.de/panorama/indien-air-india-maschine-verunglueckt-laut-medienberichten-nahe-flughafen-von-ahmedabad-a-ee140462-a413-4911-b3d1-718864754f55

The Mainz-based biotech company $BNTX (+0,44%) Biontech looks set to buy Tübingen-based competitor $CVAC (-0,22%) Curevac. Curevac is valued at around 1 billion euros. The German government is thus making a loss of around 130 million euros on its investment in Curevac, proving once again why the state is not a good investor.

https://www.focus.de/finanzen/biontech-will-deutschen-konkurrenten-curevac-uebernehmen_af5d792a-c419-4fed-b23b-4f8573d1620b.html

Friday:

Isreal's attack on Iran had been looming since yesterday. Negotiations with the USA on ending the nuclear weapons program stalled. Trump had embassy staff in Iraq withdrawn yesterday.

https://m.bild.de/politik/israel-greift-iran-an-explosionen-im-raum-teheran-684b71ab8858611e27641106

These are the most important dates for the coming week:

Wednesday: 20:00 Interest rate decision (USA)

Thursday: 13:00 Interest rate decision (UK)

Friday: 01:30 BoJ meeting minutes (Japan)

#japan
#usa
#bip
#inflation
#erzeugerpreise

SAP $SAP (-3,22%) is being targeted by the German Federal Cartel Office, which has recently launched an investigation into the acquisition of Signavio. This measure is a reaction to the accusations made by competitor Celonis, which accuses SAP of alleged misconduct. In 2021, the software giant acquired Signavio for almost one billion euros, which was approved by the regulatory authorities at the time. Signavio was a direct competitor of Celonis, and the ongoing investigations could have a lasting impact not only on the acquisition but also on SAP's entire market position. The industry is watching with interest to see how the situation will develop and what consequences this could have for SAP.

In another major move, Biontech $BNTX (+0,44%) announced the acquisition of Curevac $CVAC (-0,22%) which is seen as a significant step forward for the company. According to a pharmaceutical executive close to owners Thomas and Andreas Strüngmann, this deal reflects the strength of Biontech. At the important conference of the American Society of Clinical Oncology (ASCO) at the end of May, Biontech presented promising results that further fueled interest in the company. As part of the takeover, Curevac shares are to be exchanged for Biontech depositary receipts, which catapulted the Curevac share price up to 28 percent. As a result, the market capitalization returned to the level of the beginning of the year. Nevertheless, the valuation of Curevac shares remains 95% below the 2020 records, which shows how volatile the market for biopharmaceutical companies is.

Sources:

https://www.manager-magazin.de/unternehmen/tech/sap-bundeskartellamt-untersucht-signavio-uebernahme-nach-celonis-vorwuerfen-a-0c00eeae-8c0c-41d1-a698-c4cf526bf8c2

https://www.manager-magazin.de/unternehmen/pharma/biontech-uebernimmt-curevac-was-steckt-hinter-dem-milliarden-deal-a-e147eb69-8847-480a-8c8c-8ffab2947c7f

$CVAC (-0,22%)

I got in with a small amount last month after the sell-off. As it was still in an upward trend on the chart.

Now there were takeover rumors and the stock exploded today. This often happens with such small stocks. But I'm not deep enough into the pharmaceuticals sector to evaluate it well. I traded purely from a technical chart perspective. Would you get out here (I'll have to reset sl anyway) or keep holding?

⬆️⬆️⬆️

- BOFA raises the price target for WALMART from USD 95 to USD 105. Buy. $WMT (-0,64%)

- JEFFERIES raises the price target for WALMART from USD 100 to USD 105. Buy. $WMT (-0,64%)

- HAUCK AUFHÄUSER IB raises the target price for RHEINMETALL from EUR 680 to EUR 750. Buy. $RHM (-0,79%)

- WARBURG RESEARCH raises the target price for RHEINMETALL from EUR 600 to EUR 700. Buy. $RHM (-0,79%)

- JPMORGAN raises the price target for SALESFORCE from USD 310 to USD 340. Overweight. $CRM (-0,22%)

- WARBURG RESEARCH raises the target price for LEG IMMOBILIEN from EUR 81.60 to EUR 90.50. Hold. $LEG (-0,75%)

- DEUTSCHE BANK RESEARCH raises the price target for HEIDELBERG MATERIALS from EUR 116 to EUR 137. Buy. $HEI (+2,89%)

- KEPLER CHEUVREUX raises the price target for GFT TECHNOLOGIES from EUR 31 to EUR 32. Buy. $GFT (-1,53%)

- ODDO BHF raises the target price for TALANX from EUR 76 to EUR 78. Underperform. $TLX (-0,18%)

- KEPLER CHEUVREUX raises the target price for THYSSENKRUPP from EUR 3.70 to EUR 3.80. Hold. $TKA (+1,79%)

⬇️⬇️⬇️

- STIFEL lowers the price target for BAYER from EUR 36 to EUR 28. Hold. $BAYN (+0,56%)

- LBBW downgrades ENI from Buy to Hold and lowers target price from EUR 16.70 to EUR 15. $ENI (+1,95%)

- WARBURG RESEARCH lowers the target price for SFC ENERGY from EUR 29 to EUR 27. Buy. $F3C (+2,7%)

- WARBURG RESEARCH lowers the target price for TECHNOTRANS from EUR 23 to EUR 21. Buy. $TTR1 (+2,51%)

- DEUTSCHE BANK RESEARCH lowers the price target for CUREVAC from USD 3.90 to USD 2.50. Hold. $CVAC (-0,22%)

- BERENBERG lowers the price target for ASTRAZENECA from GBP 150 to GBP 140. Buy. $AZN (+0,1%)

MRNA - Will the new type of vaccine revolutionize the fight against cancer?

During the coronavirus pandemic, mRNA technology has impressively demonstrated how fast modern science can work.

The Artikel has sparked my interest again, perhaps an investment in this area will make sense in the coming years and not just be a gamble...

The pharmaceutical and biotech industry now seems to be focusing heavily on mRNA vaccines against cancer. For those who have never really understood how this type of vaccination works; the cure version at the end in the picture :)

Companies like BioNTech, CureVac and Moderna are currently leading the development:

$BNTX (+0,44%) , known for the first mRNA corona vaccine, is working intensively on the development of over 20 clinical programs against cancer. Some candidates are already in fortgeschrittenen Phasen and could be on the market by 2026

$MRNA (+1,86%) is currently in the lead with an mRNA vaccine against malignant melanoma. Approval could come even earlier than for BioNTech, more details also hier.

$CVAC (-0,22%) plans to bring its own mRNA cancer vaccines to market by 2028. A new partnership with the MD Anderson Cancer Center shows the potential for future innovations.

The market for mRNA therapeutics is estimated to be worth over USD 40 billion by 2033. However, the high development costs and other risks must be taken into account; more on this towards the end of the article. Artikel

#BionTech

#investieren

This article is part of an advertising partnership with Société Générale

04.07.2024 +++ NASDAQ reaches new ATH +++ Tesla with market advantage? +++ Stock market free day in the USA +++ Rheinmetall with new cooperation +++ Wirecard process with further milestone +++ Porsche limits production of e-vehicles!

After the previous day's losses, Europe's stock markets recovered strongly on Wednesday. The gained 1.2 percent to 18,375 points. Statements made by US Federal Reserve Chairman Jerome Powell the previous day at a conference in Portugal provided further support. These fueled hopes that interest rate cuts in the USA might not be too far away. The interest rate cut fantasy was reinforced by a very weak ISM service index for June in the USA. The publication of the minutes of the US Federal Reserve's latest open market meeting could now set the tone. However, the US stock markets will be closed on Thursday for a public holiday.

According to media reports, representatives of Tesla $TSLA (-3,07%) and the EU met at Tesla plants in China. The inspection lasted only three days, which could indicate that Tesla could receive a special exemption from the 21 percent tariffs on EV imports from China.

The Stuttgart-based sports car manufacturer Porsche $P911 (+2,18%) wants to limit production of its electric flagship Taycan in order to adapt to persistently weak demand for the model. According to the Stuttgarter Zeitung and Stuttgarter Nachrichten newspapers, the company intends to produce the model in single-shift operation only. Negotiations are currently underway with the works council; no job cuts are planned. A company spokesperson did not wish to comment on the information. (Stuttgarter Zeitung and Stuttgarter Nachrichten)

Rheinmetall $RHM (-0,79%) gained 4.8 percent. The armaments group wants to cooperate with the Italian armaments group Leonardo in the further development of land defense systems. The two companies want to develop Rheinmetall's new main battle tank (Panther) and the Lynx infantry fighting vehicle and then commercialize them. The project could have a volume of up to 20 billion euros. A buy recommendation from Morgan Stanley also had a supportive effect.

In the Munich Wirecard-trial has reached a milestone after more than a year and a half: the third defendant, ex-accountant Stephan von Erffa, who has remained silent since the start of the trial in December 2022, will testify to the charges for the first time on July 17. The former chief accountant of the group, which collapsed in 2020, confirmed his personal details at the start of the trial, but otherwise has not said a word on the matter during the mammoth proceedings to date. The IV. Criminal Chamber of the Munich Regional Court has promised him a prison sentence of between six and eight years in return for a confession. It is not yet clear whether the former chief accountant will admit or deny the charges in his statement. (Börsen-Zeitung)

The German Lufthansa $LHA (-1,03%) may acquire a stake in the Italian airline ITA Airways. The EU Commission approved the project, but made it a condition that a number of concessions submitted by Lufthansa and the Italian government be effectively implemented in order to ensure competition in Italian air traffic. The approval comes as no surprise from a market perspective, with the Lufthansa share closing 3.1 percent higher.

Curevac $CVAC (-0,22%) lost 1.1 percent, in early trading the shares were still up more than 20 percent. The biotech company is selling the rights to mRNA vaccine candidates to GSK and will receive an upfront payment of 400 million euros. In addition, Curevac will receive up to 1.05 billion euros in milestone payments. In addition, Curevac announced restructuring measures with the aim of reducing operating costs by more than 30 percent. Curevac is now focusing everything on the development of a cancer vaccine. Whether the biotech company will be more successful with this than with the development of a Covid-19 mRNA vaccine remains to be seen. Medical data on a promising drug should be available in the second half of the year

Thursday: Stock market dates, economic data, quarterly figures

Stock market holiday in the USA

ex-dividend of individual stocks

Iberdrola EUR 0.35

Repsol EUR 0.50

Quarterly figures / company dates Europe

10:00 AT&S AGM

12:00 Sainsbury AGM

No time specified: Baader Bank AGM

Economic data

• 08:00 DE: New orders May seasonally adjusted FORECAST: +0.9% yoy previous: -0.2% yoy
• 08:30 CH: Consumer prices June FORECAST: +0.1% yoy/+1.4% yoy previously: +0.3% yoy/+1.4% yoy
• 11:00 IT: ECB Chief Economist Lane, lecture at the University of Naples
• 16:15 IT: ECB Director Cipollone, keynote speech at national statistics conference
• Untimed: UK: UK elects new parliament

Stock analysis/Share presentation ⬇️✌🏽

Today we are talking about the company CureVac: $CVAC (-0,22%)

What is and does CureVac anyway: 🤔

CureVac is a German biopharmaceutical company focused on developing mRNA-based therapies and vaccines. They use a technology called messenger RNA to stimulate the body to produce proteins that can help fight disease. CureVac has made a particular name for itself by developing an mRNA vaccine against COVID-19. Their goal is to find innovative solutions to treat diseases and improve the health of people worldwide.

How many employees does the company have: 🙋🏽‍♂️🙋🏻‍♀️

Currently, CureVac employs a total of around 1,000 people.

Market capitalization: 🏦

Currently, CureVac has a market capitalization of around 1.53 billion euros.

Dividend yield: 💰

The company currently does not pay a dividend to its shareholders.

Strengths of the share: 📈

Some of CureVac's strengths include:

• Experience in mRNA technology: CureVac has specialized in the development of mRNA-based therapies and vaccines for many years. They have extensive knowledge and experience in this field.
• Flexibility and adaptability: CureVac's mRNA technology allows them to respond quickly to new pathogens and adapt vaccines. This is particularly important in times of pandemics or changing viruses.
• Broad range of applications: CureVac is working to develop vaccines and therapies for a variety of diseases, not just COVID-19, and its technology has the potential to play a role in combating multiple diseases.
• Partnerships and Collaboration: CureVac has strategic partnerships with other companies and organizations, including Bayer of Germany. This collaboration allows them to advance their research and development.
• Global reach: CureVac operates internationally and has collaborations and partnerships around the world. This allows them to take their technology and products global and reach people worldwide.

Weaknesses of the share: 📉

Some weaknesses of CureVac are:

• Production Capacity: Curevac currently has limited production capacity, which may affect their ability to manufacture vaccines on a large scale. This could impact its ability to efficiently meet global demand for vaccines.
• Clinical trial delays: Curevac has experienced delays in clinical trials, which may slow the process of obtaining regulatory approvals. These delays may impact the timeline for vaccine availability and distribution.
• Competition: Curevac operates in a highly competitive industry with other mRNA vaccine developers such as Pfizer and Moderna. This competition may present challenges in terms of market share and differentiation.
• Efficacy and durability: Although Curevac's vaccines have shown promising results in clinical trials, there is still uncertainty regarding their long-term efficacy and durability. Further research and monitoring are needed to determine the duration of protection provided by their vaccines.
• Distribution and logistics: as with any global vaccination program, distribution and logistics can present challenges. It is important to ensure that vaccines reach the intended populations in an efficient and timely manner.

A little more on the business model:

CureVac pursues a diverse business model based on the development and commercialization of mRNA-based therapeutics and vaccines. The company uses mRNA technology to develop innovative solutions for various diseases. An important aspect of CureVac's business model is partnering with other companies and organizations. They work closely with pharmaceutical companies, biotechnology companies, and academic institutions to further develop their technology platform and explore new therapeutic approaches. Through these partnerships, they are able to benefit from the expertise and resources of other companies to advance their research and development projects. Another important part of CureVac's business model is licensing their technology. They already have several licensing agreements with other companies that want to use their mRNA technology. Through these licensing agreements, they receive not only financial support, but also access to the resources and expertise of their partners to further develop their technology and explore new applications. CureVac is also pursuing a commercial strategy to bring their products to market. They have already completed several clinical trials and are working to obtain regulatory approval for their therapeutics and vaccines. Once their products are approved, they plan to sell them in the market and generate revenue from the sales. In addition, CureVac also has a pipeline of product candidates that are in various stages of development. They have therapeutics and vaccines in preclinical development, phase I clinical trials, phase II clinical trials, and phase III clinical trials, indicating that they are continuously working on new products and expanding their portfolio to meet medical needs.

A little more about the industry:

CureVac belongs to the biotechnology industry and specializes in the development of mRNA-based therapeutics and vaccines. The company uses the properties of messenger RNA to stimulate the body to produce specific proteins that can be used to treat diseases such as cancer, infections and rare diseases. CureVac's mRNA technology has the potential to revolutionize the way we treat disease. Through partnerships and collaborations with leading research institutions, CureVac is driving the development of new therapeutic approaches. Its goal is to find innovative solutions to improve the health and well-being of people worldwide.

When and where was CureVac founded:

CureVac was founded in 2000 in Tübingen, Germany. The company was founded by Ingmar Hoerr, Steve Pascolo and Florian von der Mülbe. CureVac is a biopharmaceutical company focused on the development of mRNA-based therapeutics and vaccines. The founders recognized the potential of mRNA technology to develop tailored treatments for various diseases. Since its founding, CureVac has made significant progress and has become a leader in mRNA research and development. They work closely with partners to find innovative solutions to medical challenges. Developing new technologies and solutions to improve energy efficiency and promote renewable energy.

CureVac's goal: 🏁

CureVac aims to develop innovative mRNA-based therapeutics and vaccines to fight disease and improve people's lives. They strive to provide customized treatments tailored to individual patient needs. By using mRNA technology, they hope to address a wide range of diseases, including cancer, infectious diseases, and rare genetic disorders. Their goal is to develop breakthrough therapies that are effective, safe and well tolerated. CureVac is working hard to shape the future of medicine and make a positive impact on the health of people worldwide.

Your opinion 🧐🤔

Now I'd love to hear your thoughts on this stock in the comments.

What do you think of CureVac and did you already know this company?

Do you guys maybe already have this stock in your portfolio?

Feel free to let me know in the comments.

This is of course not an investment advice but just my own opinion that I want to share with you.

+++ Curevac sues BioNtech and a possible reason:+++

According to concurring reports, Curevac has filed a patent infringement lawsuit with the relevant district court in Düsseldorf, Germany [see sources 1&2 below].

The lawsuit claims "intellectual property rights based on two decades of pioneering work in the field of mRNA technology." in connection with BioNTech and Pfizer's Covid-19 vaccine.

The text of the statement from Curvac is about, among other things, "several inventions considered essential to the design and development of the vaccine."

The goal of the lawsuit, however, is not to seek an injunction or take steps against "production, sale or distribution," according to Curevac.

So what now might be the request of the barely one-quarter state-owned company (23% BRD stake in the company)?

It's probably about money. Because here, too, Curevac makes it clear: "fair remuneration" is the main concern of the company from Tübingen.

Decisive for the hopeless case of a vaccine manufacturer without a vaccine might be the interesting remark on my part about the financing of the company:

Because if you follow the company's figures and their financing rounds, you quickly realize that the money for financing this loss-making company is slowly but surely running out.

Accompanied by a cash burn of around 300-310 million euros per quarter, money is likely to run out in the second half of the year at the latest, i.e. around fall 2022. The company's market capitalization can no longer help either, having fallen from 20 billion euros in April 2021 to 4 billion euros in January 2022.

Conclusion:

Curevac needs money. And since it can neither get this commercially, nor presumably through further sufficient financing rounds, it has to sue.

Unfortunately, the example of Curevac proves to me once again the overcurrent action of our politicians, who wanted to protect a company at all costs (Trump wanted to acquire the company for the USA according to rumors at the time) without having any knowledge of the matter and the state of development.

The costs will be borne by the taxpayers in the end, possibly the German government will take over the guarantee in case of a failure of further financing.

And what should be the learning effect for investors?

Well, apart from the fact that hype stocks should never be overrated, the example of Curevac should be a warning for all those who believe that first-movers always promise success. Far too often, companies that were first to market (in this case with m-RNA technology) have lost out in the end.

Sources:

Source 1: https://www.faz.net/aktuell/wirtschaft/curevac-verklagt-biontech-wegen-patentverletzung-18151025.html?premium=0x57c133b6daf202d2d2f0a76c524300a2&GEPC=s9

Source 2: https://www.curevac.com/curevac-reicht-in-deutschland-klage-gegen-biontech-wegen-patentrechtsverletzung-ein/

Source 3: https://www.curevac.com/investor-relations/finanzberichte/

Note to this opinion: I am not or have not been actively invested in either Curevac or BioNTech. However, I regularly follow news outside of my stocks and companies and form my own opinions.

$CVAC (-0,22%)

Do you think something will come again?